ALPS Advisors’s Inovio Pharmaceuticals INO Stock Holding History

ALPS Advisors’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-21,486	Closed	-$1.85M	–	928
2021 Q3	$1.85M	Sell	21,486 -1,349	-6%	-$135K	0.02%	329
2021 Q2	$2.54M	Sell	22,835 -8,470	-27%	-$814K	0.02%	256
2021 Q1	$3.49M	Buy	31,305 +6,072	+24%	+$799K	0.03%	196
2020 Q4	$2.68M	Buy	+25,233	New	+$3.36M	0.03%	230

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ALPS Advisors's INO Position: Q4 2021 in Review

ALPS Advisors sold out of Inovio Pharmaceuticals (INO) in Q4 2021, closing a stake of 21,486 shares — an estimated $1.85M sold.

ALPS Advisors first reported a position in INO in Q4 2020 and held it in 4 quarters. The position peaked at $3.49M in Q1 2021. 208 funds tracked by Wall St. Rank hold INO as of Q4 2021.

ALPS Advisors reported no remaining Inovio Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
ALPS Advisors sold 21,486 Inovio Pharmaceuticals shares in Q4 2021, an estimated $1.85M.
ALPS Advisors first reported a position in Inovio Pharmaceuticals in Q4 2020 and held it in 4 quarters.
ALPS Advisors's Inovio Pharmaceuticals position peaked at $3.49M in Q1 2021.
208 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2021.

Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.